Nocebo phenomena may be enhanced in aging: Implications for clinical practice

被引：10

作者：

Kravvariti, E. ^{[1
]}

Kotsani, M. ^{[2
]}

Mitsikostas, D. D. ^{[3
]}

Sfikakis, P. P. ^{[1
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Postgrad Med Studies Physiol Aging & Geriatr Synd, Med Sch, Athens, Greece

[2] Univ Lorraine, CHRU Nancy, Pole Malad Vieillissement Gerontol & Soins Pallia, F-54000 Nancy, France

[3] Natl & Kapodistrian Univ Athens, Aeginit Hosp, Dept Neurol 1, Sch Med, Athens, Greece

来源：

MATURITAS | 2021年 / 143卷

关键词：

Nocebo; Nocebo effects; Older adults; Geriatric care; Medication adverse effects; Negative treatment expectations; ALZHEIMERS-DISEASE; ELDERLY-PATIENTS; ADVERSE EVENTS; OLDER PATIENTS; PLACEBO; TRIALS; MECHANISMS; CARE; PERCEPTIONS; DEPRESSION;

D O I：

10.1016/j.maturitas.2020.07.011

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Nocebo effects, denoting unfavourable outcomes after a medical intervention because of negative expectations rather than a direct pharmacologic action, are an important cause of dropout from clinical trials and nonadherence to medication, and may be especially pertinent for older adults. Several characteristics of aging individuals and their medical care have a potential to augment nocebo susceptibility, such as depression and anxiety, neurodegenerative diseases and chronic pain states, adverse healthcare experiences, generic drug use, age-related stereotypes, and strained patient-physician communication. Nocebo-related research in older adults is hindered by under-representation in clinical trials, medical complexity of geriatric patients, and lack of validated tools to accurately assess susceptibility and efficacy of preventive efforts.

引用

页码：10 / 16

页数：7

共 69 条

[1] A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment [J].